AstraZeneca's Enhertu and Genentech's Perjeta combo gains breast cancer approval
Source: SeekingAlpha
2025-12-15 16:44:42 ET
More on AstraZeneca
- AstraZeneca: A Rare Compound Growth Opportunity In Biopharma
- AstraZeneca PLC 2025 Q3 - Results - Earnings Call Presentation
- AstraZeneca PLC (AZN) Q3 2025 Earnings Call Transcript
- RSV shots for infants reportedly under FDA scrutiny
- FDA top drugs official Pazdur retiring shortly after starting
Read the full article on Seeking Alpha
For further details see:
AstraZeneca's Enhertu and Genentech's Perjeta combo gains breast cancer approval
Daiichi Sankyo Co Ltd Sponsored ADR Level 1
NASDAQ: DSNKY
DSNKY Trading
-3.5% G/L:
$17.67 Last:
40,774 Volume:
$17.60 Open:
DSNKY Latest News
January 21, 2026 08:00:00 am
Daiichi Sankyo Unveils New Toronto Headquarters to Accelerate Investment and Innovation in Oncology
